Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. Sep 9, 2024; 13(3): 96877
Published online Sep 9, 2024. doi: 10.5492/wjccm.v13.i3.96877
Remimazolam in intensive care unit: Potential applications and considerations
Praveen Reddy Elmati, Teja Nagaradona, Gowthami Sai Kogilathota Jagirdhar, Salim Surani
Praveen Reddy Elmati, Department of Anesthesiology, Saint Clair Hospital, Dover, NJ 07801, United States
Teja Nagaradona, School of Medicine, St George University, Granada SW17 0BD, West Indies
Gowthami Sai Kogilathota Jagirdhar, Department of Medicine, Saint Michaels Medical Center, Newark, NJ 07107, United States
Salim Surani, Department of Medicine & Pharmacology, Texas A&M University, College Station, TX 77843, United States
Author contributions: Elmati PR designed the overall concept and outline of the manuscript; Elmati PR, Kogilathota Jagirdhar GS, Nagaradona T performed the research and analyzed the data; Elmati PR, Kogilathota Jagirdhar GS, Nagaradona T, and Surani S contributed to the manuscript's writing and editing; All authors have read and approved the final manuscript.
Conflict-of-interest statement: None of the authors have any conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Salim Surani, FCCP, MD, MS, Professor, Department of Medicine & Pharmacology, Texas A&M University, 40 Bizzell Street, College Station, TX 77843, United States. srsurani@hotmail.com
Received: May 17, 2024
Revised: June 28, 2024
Accepted: July 17, 2024
Published online: September 9, 2024
Processing time: 105 Days and 3.7 Hours
Core Tip

Core Tip: Remimazolam, an ultra-short-acting benzodiazepine, offers rapid onset, stable hemodynamics, and organ-independent metabolism, ideal for intensive care unit sedation and procedural anesthesia. Its advantages over traditional sedatives like midazolam and propofol include faster recovery, reduced hemodynamic instability, and a favorable safety profile. Remimazolam is effective for sedation in hemodynamically unstable patients and those with hepatic or renal impairment, highlighting its potential for broader clinical application. Further research is necessary to establish guidelines for its routine use.